PMID: 9159155May 27, 1997Paper

Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus

Proceedings of the National Academy of Sciences of the United States of America
R W HerzogK A High

Abstract

We sought to determine whether intramuscular injection of a recombinant adeno-associated virus (rAAV) vector expressing human factor IX (hF.IX) could direct expression of therapeutic levels of the transgene in experimental animals. High titer (10(12)-10(13) vector genomes/ml) rAAV expressing hF.IX was prepared, purified, and injected into hindlimb muscles of C57BL/6 mice and Rag 1 mice. In the immunocompetent C57BL/6 mice, immunofluorescence staining of muscle harvested 3 months after injection demonstrated the presence of hF.IX protein, and PCR analysis of muscle DNA was positive for AAV DNA, but no hF.IX was detected in mouse plasma. Further studies showed that these mice had developed circulating antibodies to hF.IX. In follow-up experiments in Rag 1 mice, which carry a mutation in the recombinase activating gene-1 and thus lack functional B and T cells, similar results were seen on DNA analysis of muscle, but these mice also demonstrated therapeutic levels (200-350 ng/ml) of F. IX in the plasma. The time course of F.IX expression demonstrates that levels gradually increase over a period of several weeks before reaching a plateau that is stable 6 months after injection. In other experiments we demonstrate colocalization of h...Continue Reading

References

Jan 1, 1992·Current Topics in Microbiology and Immunology·N Muzyczka
Oct 1, 1992·Current Opinion in Biotechnology·B J Carter
Jun 1, 1988·Journal of Virology·S K McLaughlinN Muzyczka
Mar 10, 1995·The Journal of Biological Chemistry·S KurachiK Kurachi
Mar 15, 1994·Proceedings of the National Academy of Sciences of the United States of America·M A KayA R Thompson
Apr 2, 1996·Proceedings of the National Academy of Sciences of the United States of America·J WalterK A High
Oct 1, 1996·Proceedings of the National Academy of Sciences of the United States of America·S K TripathyJ M Leiden
Oct 1, 1996·Proceedings of the National Academy of Sciences of the United States of America·W F CheungD W Stafford
Nov 1, 1996·Human Molecular Genetics·Y YangJ M Wilson
Nov 26, 1996·Proceedings of the National Academy of Sciences of the United States of America·P D KesslerB J Byrne
Mar 1, 1997·Nature Medicine·K J FisherJ M Wilson

❮ Previous
Next ❯

Citations

Mar 28, 2001·The Journal of Gene Medicine·L DrittantiM Vega
Mar 28, 2001·The Journal of Gene Medicine·M K ChuahT VandenDriessche
Dec 5, 2002·International Journal of Hematology·Katherine A High
Apr 14, 2006·Human Genetics·Kenneth H Warrington, Roland W Herzog
Dec 21, 2000·Current Atherosclerosis Reports·D J Rader, U J Tietge
Jun 2, 2005·Cancer Letters·Christian J StreckAndrew M Davidoff
Feb 1, 2003·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Wenyin ShiDietmar W Siemann
Feb 21, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kazuyoshi Sagara, Sung Wan Kim
Aug 16, 2000·Advanced Drug Delivery Reviews·P A TrescoM D Noble
Jun 6, 2000·Advanced Drug Delivery Reviews·K M Bowie, P L Chang
Feb 9, 2000·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·E ShinyaD Klatzmann
Dec 3, 2002·Current Opinion in Biotechnology·Richard O Snyder, Terence R Flotte
Nov 20, 1998·Current Opinion in Biotechnology·J E Rabinowitz, J Samulski
Aug 5, 1998·Current Opinion in Genetics & Development·D J Marshall, J M Leiden
Oct 30, 1998·Critical Reviews in Oncology/hematology·M K ChuahT VandenDriessche
Oct 13, 2000·Progress in Retinal and Eye Research·W W Hauswirth, A S Lewin
Oct 25, 2003·Progress in Retinal and Eye Research·Enrico M Surace, Alberto Auricchio
Feb 22, 2001·Drug Discovery Today·S C. GhivizzaniC H. Evans
Apr 2, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Bernd HauckWeidong Xiao
Mar 26, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Zhaobing DingBeat Thöny
Oct 23, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Bernd HauckJ Fraser Wright
Jan 8, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Lingxia ChenWeidong Xiao
Jul 16, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ou CaoRoland W Herzog
Nov 6, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Alice ToromanoffCaroline Le Guiner
May 19, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hua LiHildegund C J Ertl
Sep 13, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Adeline VulinLuis Garcia
Jul 18, 2006·Nature Biotechnology·Alex H ChangMichel Sadelain
May 20, 1998·Nature Genetics·C H MiaoM A Kay
Oct 4, 2003·Nature Reviews. Genetics·Judith C T van Deutekom, Gert-Jan B van Ommen
Jun 18, 2005·Cancer Gene Therapy·Chengwen LiRichard Jude Samulski
Jun 15, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Denise E SabatinoKatherine A High
Oct 24, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Samuel L MurphyKatherine High
Apr 23, 2002·Haemophilia : the Official Journal of the World Federation of Hemophilia·C E Walsh, H Chao
Feb 15, 2002·British Journal of Haematology·K J Pasi
Jan 5, 1999·Haemophilia : the Official Journal of the World Federation of Hemophilia·P A Fields, K J Pasi
Jan 5, 1999·Haemophilia : the Official Journal of the World Federation of Hemophilia·D Lillicrap

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.